Skip to main content
. 2023 Jun 6;18(4):517–530. doi: 10.1007/s11523-023-00965-7
This phase Ib study assessed the safety, tolerability, and antitumor activity of adavosertib monotherapy in patients with advanced solid tumors.
Adavosertib demonstrated some antitumor activity in heavily pretreated patients with advanced solid tumors.
The safety and tolerability profile of adavosertib monotherapy was considered manageable.